NFA
CRVS icon

Nationwide Fund Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Nationwide Fund Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-74,513
Closed -$1.19M – 483
2017
Q3 		$1.19M Sell
74,513
-2,300
-3% -$31.8K ﹤0.01% 1688
2017
Q2 		$929K Buy
76,813
+56,856
+285% +$607K ﹤0.01% 1819
2017
Q1 		$415K Sell
19,957
-3,600
-15% -$56.4K ﹤0.01% 2249
2016
Q4 		$337K Sell
23,557
-1,000
-4% -$15.2K ﹤0.01% 2374
2016
Q3 		$404K Sell
24,557
-2,500
-9% -$36K ﹤0.01% 2276
2016
Q2 		$386K Buy
+27,057
New +$365K ﹤0.01% 2286

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return